Stockreport

MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ... [Yahoo! Finance]

MiNK Therapeutics, Inc.  (INKT) 
PDF Net Loss (Q4 2025): $2.6 million or $0.56 per share. Net Loss (Full Year 2025): $12.5 million or $2.93 per share. Operating Cost: Decreased nearly 40% over the year [Read more]